Hikma Pharmaceuticals (LON:HIK) Hits New 52-Week Low – What’s Next?

Hikma Pharmaceuticals PLC (LON:HIK) hit a new 52-week low during mid-day trading on Friday . The stock traded as low as GBX 1,353 and last traded at GBX 1,391.08, with a volume of 3827154 shares traded. The stock had previously closed at GBX 1,652.

Key Headlines Impacting Hikma Pharmaceuticals

Here are the key news stories impacting Hikma Pharmaceuticals this week:

• Positive Sentiment: Group revenue rose 7% to $3.349 billion for 2025, a top‑line beat that supports underlying business momentum. Jordan: Hikma posts 7% revenue rise at $3.349bln in 2025
• Positive Sentiment: The company reported group profit/EBITDA strength and announced a share buyback, which is shareholder‑friendly and can support EPS. Hikma delivers Group revenue and profit growth and announces share buyback and leadership changes
• Neutral Sentiment: Management changes: the company has named its chair as chief executive — a material governance move that investors will watch for execution risk and strategic continuity. Hikma names chair chief executive
• Neutral Sentiment: Full‑year earnings call highlighted solid EBITDA and operational points, but commentary on margins and near‑term trends was cautious. Hikma Pharmaceuticals PLC (HKMPF) Full Year 2025 Earnings Call Highlights: Strong EBITDA …
• Negative Sentiment: Management warned of slower growth and cut guidance for the outlook; that guidance revision is cited as the primary reason for the sharp share price decline. Hikma’s shares plummet after guidance cut
• Negative Sentiment: Analysts and media flagged a margin warning tied to 2026 expectations — one report notes the stock fell ~17% on margin concerns despite results being broadly in line. Hikma posts 2025 results in line; stock down 17% on margin warning
• Negative Sentiment: Market commentary highlights a gloomy near‑term outlook and the stock’s immediate underperformance versus peers, reinforcing the negative market reaction. Hikma Pharmaceuticals falls Thursday, underperforms market

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Deutsche Bank Aktiengesellschaft dropped their target price on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a “buy” rating for the company in a research note on Friday, January 9th. Berenberg Bank reissued a “buy” rating and set a GBX 2,300 price target on shares of Hikma Pharmaceuticals in a research note on Thursday, January 22nd. Peel Hunt reaffirmed a “buy” rating and issued a GBX 2,170 price objective on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. JPMorgan Chase & Co. lowered their target price on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a report on Friday, November 7th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,360 target price on shares of Hikma Pharmaceuticals in a research report on Friday, November 7th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Hikma Pharmaceuticals has a consensus rating of “Buy” and an average price target of GBX 2,326.

Hikma Pharmaceuticals Stock Performance

The stock has a market cap of £2.91 billion, a price-to-earnings ratio of 7.87, a PEG ratio of 2.38 and a beta of 0.41. The stock’s fifty day moving average is GBX 1,554.51 and its 200-day moving average is GBX 1,641.11. The company has a quick ratio of 1.27, a current ratio of 1.66 and a debt-to-equity ratio of 55.82.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.